Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 13 Mar 2023
Harrow announces transitional pass through reimbursement status for Iheezo (chloroprocaine hydrochloride 3% ophthalmic gel)
13 March 2023 - Harrow today announced that the Centers for Medicare & Medicaid Services has approved transitional pass-through reimbursement ...
Posted by Michael Wonder on 12 Mar 2023
Medicare doesn’t pay for obesity drugs: lifting this coverage prohibition faces considerable hurdles
11 March 2023 - A number of different stakeholders across the healthcare landscape are lobbying legislators and the Centers for Medicare ...
Posted by Michael Wonder on 12 Mar 2023
The value of medical innovation versus industry rewards
10 March 2023 - This article provides systematic evidence on the share of the value of health generated by drugs and ...
Posted by Michael Wonder on 12 Mar 2023
By cutting insulin prices, Eli Lilly avoids paying big Medicaid rebates
6 March 2023 - Eli Lilly would’ve had to pay Medicaid about $150 for each vial of insulin used in ...
Posted by Michael Wonder on 12 Mar 2023
‘When’s our turn?’ PHARMAC's new funding won't cover breast cancer fighter's $100k bill
13 March 2023 - Hayley Steele has a hefty price tag on her life, one worth almost $100,000. ...
Posted by Michael Wonder on 12 Mar 2023
Medicare Part D coverage of anti-obesity medications — challenges and uncertainty ahead
11 March 2023 - Obesity is highly prevalent in the United States — affecting more than 41% of adults, including a ...
Posted by Michael Wonder on 11 Mar 2023
Drug pricing throughout the product lifecycle: a work in progress
10 March 2023 - Increases in drug prices and drug spending are of concern to health systems worldwide. This has naturally ...
Posted by Michael Wonder on 11 Mar 2023
Maxigesic Rapid tablets gain US FDA approval
10 March 2023 - AFT Pharmaceuticals today announces the US FDA has approved a rapid release tablet form of Maxigesic ...
Posted by Michael Wonder on 11 Mar 2023
COVID-19 vaccine safety report (9 March 2023)
9 March 2023 - To 5 March 2023, over 44 million doses have been administered in Australia, as well as about ...
Posted by Michael Wonder on 11 Mar 2023
Acadia Pharmaceuticals announces US FDA approval of Daybue (trofinetide) for the treatment of Rett syndrome in adult and paediatric patients two years of age and older
10 March 2023 - Company expects Daybue to be available by the end of April 2023. ...
Posted by Michael Wonder on 10 Mar 2023
Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices.
10 March 2023 - By law, Medicare will have to take a medication’s efficacy and its research and development costs ...
Posted by Michael Wonder on 10 Mar 2023
Pfizer’s Zavzpret (zavegepant) migraine nasal spray receives FDA approval
10 March 2023 - Zavzpret is the first and only calcitonin gene-related peptide receptor antagonist nasal spray for the acute treatment ...
Posted by Michael Wonder on 10 Mar 2023
Alberta’s import of children’s medication to cost taxpayers $80 million
9 March 2023 - Alberta taxpayers are on the hook for $80 million, after Health Minister Jason Copping finally revealed ...
Posted by Michael Wonder on 10 Mar 2023
ICER to assess gene therapy for metachromatic leukodystrophy
9 March 2023 - Report will be subject of CTAF meeting in September 2023; draft scoping document open to public ...
Posted by Michael Wonder on 10 Mar 2023
Will NZ neurological drug Trofinetide for Rett syndrome get US FDA approval and make history?
10 March 2023 - Kiwi scientists may be about to make New Zealand history, with a breakthrough treatment on the ...